HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.1%

Neg 0% Neu 91.1% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $358 price target.